# EDGAR Filing Document

**Accession Number:** 0001556914
**File Stem:** 0001209191-23-017720
**Filing Date:** 2023-3
**Character Count:** 9222
**Document Hash:** 047306780fabf5be9aaefd474dcf49f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-017720.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001209191-23-017720

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230310

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Marek David C
- **CENTRAL INDEX KEY:** 0001556914

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37929
- **FILM NUMBER:** 23721874

**MAIL ADDRESS:**
- **STREET 1:** C/O WEBMD HEALTH CORP.
- **STREET 2:** 111 EIGHTH AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Myovant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001679082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 0331

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB
- **BUSINESS PHONE:** 44 207-400-3351

**MAIL ADDRESS:**
- **STREET 1:** SUITE 1, 3RD FLOOR
- **STREET 2:** 11-12 ST. JAMES SQUARE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW1Y 4LB

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Marek David C<br><sub>(Last) (First) (Middle)</sub><br>C/O MYOVANT SCIENCES, INC.<br>2000 SIERRA POINT PARKWAY, 9TH FLOOR<br><sub>(Street)</sub><br>BRISBANE, CA 94005<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-10 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Principal Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Myovant Sciences Ltd. [ MYOV ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Shares | 2023-03-10 |  | D<sup>(1)</sup> |  | 95675 | D | <sup>(2)</sup> | 321924 | D |  |
| Common Shares | 2023-03-10 |  | D<sup>(1)</sup> |  | 321924 | D | <sup>(3)</sup> | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to Buy) | $20.54 | 2023-03-10 |  | D<sup>(1)</sup> |  |  | 306427 | <sup>(4)</sup> | 2031-01-14 | Common Shares | 306427 | <sup>(5)</sup> | 0 | D |  |
| Stock Options (Right to Buy) | $17.88 | 2023-03-10 |  | D<sup>(1)</sup> |  |  | 208218 | <sup>(6)</sup> | 2031-04-14 | Common Shares | 208218 | <sup>(5)</sup> | 0 | D |  |
| Stock Options (Right to Buy) | $11.33 | 2023-03-10 |  | D<sup>(1)</sup> |  |  | 204808 | <sup>(7)</sup> | 2032-04-14 | Common Shares | 204808 | <sup>(5)</sup> | 0 | D |  |
| Performance Stock Unit | <sup>(8)</sup> | 2023-03-10 |  | D<sup>(1)</sup> |  |  | 134567 | <sup>(8)</sup> | <sup>(8)</sup> | Common Shares | 134567 | <sup>(8)</sup> | 0 | D |  |

---

### Footnotes:

(1) On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

(2) At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration").

(3) Reflects restricted stock units ("RSUs").  Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time.

(4) One-fourth of the options vested on January 15, 2022, and one-sixteenth of the options vest each quarter thereafter.

(5) Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

(6) One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter.

(7) One-fourth of the options are scheduled to vest on April 15, 2023, and one-sixteenth of the options are scheduled to vest each quarter thereafter.

(8) Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.

**Signature:** /s/  Matthew Lang, Attorney-in-fact  
**Date:** 2023-03-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**